Predictors of Successful Cardioversion with Vernakalant in Patients with Recent‐Onset Atrial Fibrillation

BACKGROUND: Vernakalant is a novel atrial‐selective antiarrhythmic drug able to convert recent‐onset atrial fibrillation (AF) with reportedly low proarrhythmic risk. Successful cardioversion predictors are largely unknown. We sought to evaluate clinical and electrocardiographic predictors of cardiov...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Noninvasive Electrocardiol
Hlavní autoři: Mochalina, Natalia, Juhlin, Tord, Öhlin, Bertil, Carlson, Jonas, Holmqvist, Fredrik, Platonov, Pyotr G.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2014
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931769/
https://ncbi.nlm.nih.gov/pubmed/25040826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/anec.12178
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky